In mid-August 2019 it was announced that GraphPad Software had acquired SnapGene, a leading bioinformatics software solution aka as GSL Biotech LLC Developed by scientists and software designers to meet the everyday needs of molecular biologists. SnapGene desktop software (snapgene.com) is used in more than sixty-five countries, in virtually every major research institution, and in most of the largest pharmaceutical and biotech companies worldwide. The software provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology Developed by Benjamin Glick, Ph.D., Pesident of the firm and a professor at the University of Chicago - who became frustrated by inefficiencies and inadequate procedures he experienced in his work, since launch of the product in 2012, the company has seen rapid adoption of its innovative DNA cloning solutions designed to enhance the research workflow. DNA cloning underlies all of biomedical research, yet cloning procedures often fail because they involve a large number of variables and are hard to document with existing tools. Even when a procedure is successful, the verification may be done incorrectly. This situation impedes progress and forces scientists to divert attention from more creative activities. The founders of GSL Biotech realized that these problems could be solved with well crafted software. The company's software keeps track of the relevant variables, and provides key information at each step of a cloning simulation, thereby streamlining the design and documentation of DNA cloning procedures. SnapGene (GSL Biotech) will function as a subsiduary of Graphpad software.
